Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma

Current Oncology Reports

Volumn 16, Issue 8, 2014, Pages

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Advanced hepatocellular carcinoma; HCC; Hepatocellular carcinoma; Oncology; Oxaliplatin

Indexed keywords

OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; LIVER CELL CARCINOMA; NOTE; PERSONAL EXPERIENCE; SYSTEMIC THERAPY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901576120     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0394-0     Document Type: Note

References (21)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Llovet JM, Ricci S, Mazaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
3. Chang AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
4. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Cancer Inst. 2013;25(4):165-71. doi:10.1016/j.jnci.2013.08.002. Epub 2013 Sep 21.
5. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013;30(3):655. doi:10.1007/s12032-013- 0655-z. Epub 2013 Jul 4.
6. Abdel-Rahman O, Elsayed Z. Combination transarterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci. 2013;58(12):3389-96. doi:10.1007/s10620-013-2872-x. Epub 2013 Sep 18.
7. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit Rev Oncol Hematol. 2014. doi:10.1016/j.critrevonc.2013.12.013.
8. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev Anticancer Ther. 2014. doi:10.1586/14737140.2014. 894465.
9. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egypt Natl Canc Inst. 2014;26(1):9-13. doi:10.1016/j.jnci.2013.08.003. Epub 2013 Sep 16.
10. Qin S, Bai Y, Ye S, et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol. 2010;28:15 (abstr 4008).
11. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer: a California cancer consortium trial. Am J Clin Oncol. 2008;31(4):317-22. doi:10.1097/COC.0b013e318162f57d.
12. Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58(1):81-8. doi:10.1016/j.jhep.2012.09.006. Epub 2012 Sep 16.
13. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109(7):1384-90. (Pubitemid 46466566)
14. Patrikidou A, Sinapi I, Regnault H, et al. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs. 2014 Apr 22. [Epub ahead of print].
15. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112(12):2733-9. doi:10.1002/cncr.23489. (Pubitemid 351969218)
16. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898-903. (Pubitemid 46638989)
17. Assenat E, Boige V, Thézenas S, et al. Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial). J Clin Oncol 31, 2013 (suppl; abstr 4028). Assenat and colleagues evaluated GEMOX plus sorafenib in a randomised phase II study. They found that this combination was feasible in HCC and the trial met its primary endpoint (4-mo PFS ≥ 50%) and ORR, median PFS and OS were encouraging. Exploratory analyses are underway to identify subgroups of patients likely to derive most benefit from this combination.
18. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007;97(7):862-7. (Pubitemid 47519302)
19. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 2011;117(14):3187-92. doi:10.1002/cncr.25889. In this study, Sun and co-workers conducted a phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in advanced HCC. The combination appeared effective and safe, with encouraging results.
20. Yau T, Cheung F, Lee F, et al. A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. J Clin Oncol 31, 2013 (suppl; abstr 4117) In this study, Yau and co-workers evaluated the combination of sorafenib, capecitabine, and oxaliplatin (SECOX) in a phase 2 study in Asian patients with advanced hepatocellular carcinoma. They found that the SECOX regime has promising activity and safety in an Asian population with advanced HCC.
21. Clinicaltrials.gov record: http://clinicaltrials.gov/ct2/show/ NCT0124558212.